I mean, we have to remember that about 90%, 95% of the workflow is identical between a gene therapy infusion as a DBS procedure. So every one of these clinical procedures we’re doing today is really preparing and training a site to be capable of doing clinical trial cases in the future, which is kind of another draw on where the technology goes from.
William Wood: Got it. Yes, that’s very helpful. Kind of sticking in that same vein, I mean, you had a lot of growth in the BBD revenue which was largely based on the disposable and services related to preclinical and clinical as you were just kind of discussing, in that preclinical use and maybe even the clinical, do you feel that the growth in that disposable and services, is that related to larger studies getting underway or more studies or more partners beginning to use your products? So is it more partnerships or just more general use?
Joe Burnett: Yes. I think it’s – I think of it more as the progression of the maturity of these different cell and gene therapy candidates. So what I mean by that is generally in your first engagement with a customer, we might do a little bit of prototyping, we might test compatibility, but there’s not a big revenue opportunity for us in year one. You start to compare that to year two, year three, and year four, then we start saying, okay, now we’re doing repeatability testing. Now we’re doing toxicology testing and flow control studies and things like that, any of which sometimes could be 15, 20, as many as 50 different navigation systems and cannulas that are used in some of these studies. So as a customer continues to make progress on their drug, generally the revenue opportunity for us continues to expand as well.
So I would say to kind of answer your question, I would say of that growth that we saw here in Q1, the majority of that is existing customers that are progressing in their drug development with a – with the addition of number of new customers as well, or new partners that just started their very first engagement with ClearPoint. So it’s a combination, but it’s definitely heavily weighted towards existing customers and their progression.
William Wood: Got it. Appreciate that. And thanks for taking on questions.
Joe Burnett: Yes, sure. Thanks, Will.
Operator: Thank you. There are no further questions at this time. I’d like to hand the floor back over to Joe Burnett for any closing comments.
Joe Burnett: Once again, thank you to everyone interested in being a part of our team and our journey here at ClearPoint. As we showed in Q1, we believe 2024 is going to be an exciting year as we earn new customers, grow same-store sales with new product launches, and solidify important strategic partnerships with new and existing biotech partners. We expect to impact significantly more lives this year than in years past, and we are thrilled to work at the company which can impact so many patients in so many different ways. Thank you and good night.
Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.
